AlphaYou
Overview
Smart money at a glance
Filings to Oct 12, 2026Net selling: insiders sold $8.2M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net selling of $16K to $65K in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$8.2M netNet selling
- CongressSTOCK Act, last 180 days
- -$16K to -$65K netNet selling
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 11 added, 2 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- 7 awardsAwards on record
Market overview
Fundamentals Oct 11- Open
- $271.53
- 52-wk high
- $277.60
- High
- $277.60
- 52-wk low
- $189.40
- Low
- $270.38
- Prev close
- $272.42
- Mkt cap
- $488.55B
- P/E
- 78.1x
- Volume
- 4.26M
- Fwd P/E
- 16.4x
- Beta
- 0.23
- Div yield
- 2.51%
- P/S
- 7.6x
- P/B
- 50.5x
- Profit margin
- +9.8%
- Op margin
- +40.0%
- ROE
- +62.3%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about ABBV filings
Are insiders buying or selling AbbVie Inc (ABBV) stock?
Net selling: insiders sold $8.2M and bought $0 of ABBV stock on the open market in the 90 days to Oct 12, 2026, according to SEC Form 4 filings. The largest was Donoghoe, Nicholas (EVP, Chief Bus/Strat Officer), who sold $8.2M. The latest filing was on Aug 18, 2026.
Which members of Congress have traded ABBV recently?
Rep. Pete Sessions (R) sold $15K to $50K on Sep 14, 2026, disclosed 4 days later. Rep. Josh Gottheimer (D) sold $1K to $15K on May 5, 2026, disclosed 29 days later. In total, 2 members disclosed 2 ABBV trades with trade dates in the last 180 days, filed a median 17 days after trading.
How current is this ABBV smart-money data?
This summary uses filings available on Oct 12, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (3)
- CI
Citadel
$691.0M
added
- DS
D.E. Shaw
$382.7M
added
- AQ
AQR
$313.8M
added
What insiders are doing
Sells (1)
- DN
Donoghoe Nicholas
$8.2M
sold
What Congress is doing
Sells (2)
How top traders are positioned
No tracked top-trader positions in ABBV right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 1.2% above what analysts expected.
Last report
Jul 31, 2026
Financial period
Q2
Adjusted EPS
$3.61 expected
Revenue
$16.76B expected
At a glance
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 31, 2026 | $3.65 / $3.61Yahoo Finance | +1.15% beat | $16.99B / $16.76B | +1.36% beat |
| Mar 31, 2026 | Apr 29, 2026 | $2.65 / $2.67Yahoo Finance | -0.77% in line | Unavailable | Unavailable |
| Dec 31, 2025 | Feb 4, 2026 | $2.71 / $2.65Yahoo Finance | +2.16% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Oct 31, 2025 | $1.86 / $1.78Yahoo Finance | +4.23% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Jul 31, 2025 | $2.97 / $2.91Alpha Vantage | +2.06% beat | Unavailable | Unavailable |
| Mar 31, 2025 | Apr 25, 2025 | $2.46 / $2.40Alpha Vantage | +2.50% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Jan 31, 2025 | $2.16 / $2.12Alpha Vantage | +1.89% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Oct 30, 2024 | $3.00 / $2.92Alpha Vantage | +2.74% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Reports Oct 30, 2026, in 18 days
Estimates as of Oct 11, 2026
EPS expected
$3.77 to $3.87
Revenue expected
18 analysts
Last 30 days
Analysts cutting estimates
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $15.78B | $16.62B | $15.00B | $16.99B |
| Cost of what it sold | $5.30B | $4.55B | $4.22B | $4.29B |
| Gross profit | $10.47B | $12.07B | $10.78B | $12.70B |
| What it spent | ||||
| Research and development | $2.32B | $2.58B | $2.47B | $2.34B |
| Sales and admin | $3.57B | $3.90B | $3.58B | $3.63B |
| Other operating costs | $2.68B | -$217.0M | — | $291.0M |
| Total operating expenses | $8.57B | $6.26B | $6.05B | $6.27B |
| What was left | ||||
| Operating profit | $1.90B | $5.81B | $4.73B | $6.43B |
| Interest on debt | $739.0M | $714.0M | $717.0M | $746.0M |
| Profit before tax | $714.0M | $2.67B | $1.04B | $4.28B |
| Tax | $526.0M | $853.0M | $342.0M | $662.0M |
| Net profit | $186.0M | $1.82B | $699.0M | $3.61B |
| EBITDA | $3.52B | $5.37B | $3.69B | $8.61B |
Technicals
Price structure
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
93.3% of Crohn’s patients with fistulas who stayed on AbbVie’s RINVOQ reached clinical and steroid-free remission.
BullishOct 11Amgen (AMGN) Stock Could Be 39% Undervalued Following KRAS Market Growth
NeutralOct 11Regeneron Pharmaceuticals (REGN) Gets A Fresh Look As Trial Wins And Sanofi Deal Feed Value Narrative
NeutralOct 10AbbVie's Experimental Cancer Drug Temab-A Earns Two FDA Breakthrough Designations for Advanced Colorectal and Lung Cancers
BullishOct 10AbbVie Inc. (1ABBV.MI) Stock Price, News, Quote & History
BullishOct 10Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Alkermes (ALKS)
BullishOct 10Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Alkermes (ALKS)
NeutralOct 10AbbVie stock trades 0.90 percent above its Xetra close of EUR 244.40 in weekend trading
BullishOct 10